Literature DB >> 20654055

[Clinical analysis of primary extraocular muscles tumors].

Yan-jin He1, Ting-ting Lin, Guo-xiang Song, Hong Zhang.   

Abstract

OBJECTIVE: To analyze the clinical manifestation of primary extraocular muscles tumors and to study the diagnosis and therapy of this disorder.
METHODS: Retrospective analysis of the clinical data of all primary extraocular muscles tumors (the diagnosis was confirmed by operation and pathological examination) in our hospital.
RESULTS: There were 9 cases of primary extraocular muscle tumors. Six cases involved the internal rectus, 2 cases involved the external rectus, 1 case involved both inferior rectus and inferior oblique. Three cases involved the total length of the muscle; 2 cases involved the anterior muscle tendon and belly, 3 cases involved the posterior muscle tendon and belly, 1 case involved the muscle belly only. There were 3 cases of venous hemangioma, 2 cases of fibroangioma, 2 cases of neurilemoma, 1 case of fibrous histiocytoma and 1 case of paraganglioma. Image examination showed significant enlargement of extraocular muscle with clear boundary. B-scan ultrasonography, color Doppler flow image, CT and MRI scan showed different features. Patients were treated by excision of the tumor. Transplantation of the rectus was performed in several cases after the excision of the muscle.
CONCLUSIONS: Vascular tumors are the most common type of primary extraocular muscle tumors. Congestion and swelling can be observed at the insertion of the rectus. The eyeball is proposed and moved to the opposite side of the affected muscle. Changes in the image analysis are related to the pathologic features. A good therapeutic results can be achieved by surgical excision of the tumor.

Entities:  

Mesh:

Year:  2010        PMID: 20654055

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  1 in total

1.  Orbital venous hemangioma.

Authors:  Toshinobu Kubota; Suzuko Moritani; Hiroko Terasaki
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-01-14       Impact factor: 3.117

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.